Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascelia Pharma AB ( (SE:ACE) ) just unveiled an announcement.
Ascelia Pharma has filed a new patent application for Orviglance, an innovative liver imaging drug designed to enhance the detection of liver lesions in patients with reduced kidney function. This patent aims to extend market protection for Orviglance until 2046, potentially boosting its commercial value and strengthening Ascelia Pharma’s position in the market.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs to address unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm. It has two drug candidates, Orviglance and Oncoral, in development.
YTD Price Performance: 2.91%
Average Trading Volume: 1,538,379
Technical Sentiment Signal: Sell
Current Market Cap: SEK381.1M
See more data about ACE stock on TipRanks’ Stock Analysis page.